EyeCatching Stock: Americann Inc (ACAN), American Cannabis Company Inc (AMMJ), Earth Science Tech Inc (ETST)

EyeCatching Stock: Americann Inc (ACAN), American Cannabis Company Inc (AMMJ), Earth Science Tech Inc (ETST)

EyeCatching Stock: Americann Inc (ACAN), American Cannabis Company Inc (AMMJ), Earth Science Tech Inc (ETST)

Americann Inc (OTCMKTS:ACAN) showing dropped of -2.34% and closed at $4.17, after gaining total volume of 34,243.00 shares. Its earnings per share (EPS) are -$0.13 and it has total market capitalization of $80.34 million and a total of 19.13 million outstanding shares.

AmeriCann, Inc. focuses on providing consulting, design, construction, and financing to marijuana operators in the United States. The company was formerly known as Nevada Health Scan, Inc. and changed its name to AmeriCann, Inc. in February 2014. AmeriCann, Inc. was founded in 2010 and is based in Denver, Colorado.

American Cannabis Company Inc (OTCMKTS:AMMJ) decreased -2.84% closed at $0.651 and traded with total volume of 383,386.00 shares, while the average trading remained 644,663.00 shares. During last trade its minimum price was $0.65 and it gained the highest price of $0.70. Its market capitalization was $30.47 billion.

American Cannabis Company Inc (AMMJ) on March 22, 2017 announced that five of its active clients have successfully submitted application materials and supporting documents for the purpose of acquiring business licenses to operate within the newly founded medical cannabis program that is to be regulated by the State of Pennsylvania.

Of the Company’s five active clients in Pennsylvania, two clients have applied for licenses to legally dispense medical cannabis, one client has applied for a license to legally cultivate medical cannabis, and two clients have opted to apply for dual licensure to vertically integrate legal cultivation and dispensary operations.

Terry Buffalo, CEO of American Cannabis Company, commented: “We are pleased to be working with such dedicated and driven clients who want to see their businesses flourish. It takes a knowledgeable project management team and motivated client to produce, organize and finalize these application materials, and we feel that each of our active clients in Pennsylvania are prepared to succeed in this new market.”

Earth Science Tech Inc (OTCMKTS:ETST) reported the plunge of -14.57% and closed at $1.70, with the total traded volume of 46,689.00 shares. During last trade its minimum price was $1.70 and it gained its highest price of $1.99 and has a total of -0.05 million outstanding shares.

On March 6, 2017 Earth Science Tech, Inc. (ETST), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices based company is proud to announce that its wholly owned subsidiary Cannabis Therapeutics timeline for its cannabis cannabinoid-based nutraceutical patent and generic pharmaceutical drug completion.

At a meeting with the company’s Advisory Board on Tuesday, February 28th at Le Centre Québecois d’Innovation en Biotechnologie (CQIB) in Laval, Québec; the scientists concluded that the improved CBD Hemp Oil food supplement was ready to move to prototyping, and then to be fast tracked to commercialization. In addition, two cannabinoid-based generic pharmaceutical drugs will be ready for pre-market clinical trials related to drug bioavailability by Q3 2017. Depending on the time needed to properly conduct the clinical trials, both of the pharmaceutical drugs looks to be completed by the end of 2017 or beginning of 2018.

The first or these two generic drugs, an anti-breast cancer drug, is an important advance for the company as breast cancer affects more women worldwide than any other cancer. The components of the anti-breast cancer drug that Cannabis Therapeutics is bringing to market are contained in the World Health Organization’s current Model List of Essential Medicines (2015). The WHO Model Complementary List indicates the essential medicines needed to treat priority diseases, such as breast cancer, by any healthcare system.



Leave a reply


There are no comments on this post.